BioArctic AB (publ) (BRCTF)
OTCMKTS · Delayed Price · Currency is USD
29.47
-0.29 (-0.99%)
Sep 15, 2025, 2:24 PM EDT
BioArctic AB Employees
BioArctic AB had 107 employees as of December 31, 2024. The number of employees increased by 19 or 21.59% compared to the previous year.
Employees
107
Change (1Y)
19
Growth (1Y)
21.59%
Revenue / Employee
$1,643,315
Profits / Employee
$942,840
Market Cap
2.57B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 107 | 19 | 21.59% |
Dec 31, 2023 | 88 | 27 | 44.26% |
Dec 31, 2022 | 61 | 12 | 24.49% |
Dec 31, 2021 | 49 | 4 | 8.89% |
Dec 31, 2020 | 45 | 3 | 7.14% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
Elite Pharmaceuticals | 68 |
Tian'an Technology Group | 8 |
Glass House Brands | 374 |
Northwest Biotherapeutics | 25 |
CytoDyn | 13 |
American Oncology Network | 1,914 |
Silence Therapeutics | 116 |
BioArctic AB News
- 6 days ago - BioArctic: Gunilla Osswald awarded Uppsala University Alumnus of the year 2025 - PRNewsWire
- 12 days ago - BioArctic's founders intend to divest minor part of their shareholding - PRNewsWire
- 12 days ago - Rolling sBLA initiated to the U.S. FDA for Leqembi® Iqlik™ (lecanemab-irmb) as a subcutaneous starting dose for the treatment of early Alzheimer's disease under Fast Track status - PRNewsWire
- 16 days ago - US FDA approves Leqembi® IQKLIK ™ (lecanemab-irmb) subcutaneous injection for maintenance dosing for the treatment of early Alzheimer's disease - PRNewsWire
- 18 days ago - BioArctic: Interim Report for the period April - June 2025 - PRNewsWire
- 20 days ago - BioArctic and Novartis sign an option, collaboration and license agreement using BrainTransporter™ for an upfront payment of USD 30 million plus additional potential milestones and royalties - PRNewsWire
- 21 days ago - Leqembi® (lecanemab) launched in the EU today - PRNewsWire
- 25 days ago - Invitation to presentation of BioArctic's second quarter report for April - June 2025 on August 28 at 9.30 a.m. CET - PRNewsWire